srch

International Journal of Pharmaceutics · The Impact Factor of this journal is 5.875, ranking it 37 out of 275 in Pharmacology & Pharmacy · With this journal ...

Indexed in the Multidisciplinary Sciences JCR category and by EBSCOhost, Academic Search Complete, TOC Premier (Table of Contents), OCLC, Arts and Humanities ...

Pharmaceutics 2022, 14(1), 189; https://doi.org/10.3390/pharmaceutics14010189 (registering DOI) - 13 Jan 2022. Abstract. Over the last decade, ...

Company. JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials.

16.11.2021 · Pharmaceutics is a journal covering the technologies/fields/categories related to Pharmaceutical Science (Q1). It is published by MDPI Multidisciplinary Digital Publishing Institute. The overall rank of Pharmaceutics is 4054 . According to SCImago Journal Rank (SJR), this journal is ranked 1.054.

JCR USA, Inc. (JCR USA) is a joint venture company of two Japanese companies both of which are publicly listed on the Tokyo Stock Exchange. One of which is JCR Pharmaceutical Co., Ltd. (JCR) who owns 65% of JCR USA.

JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan JCR Pharmaceutical announced that the Ministry of Health, Labour and Welfare...

01.07.2021 · Impact Factor List of Journals For 2021 by JCR - CA-A CANCER JOURNAL FOR CLINICIANS - 508.7, Nature Reviews Molecular Cell Biology - 98.4, New

31.12.2021 · Pharmaceutics The 2020-2021 Journal Impact IF of Pharmaceutics is 6.072, which is just updated in 2021. Pharmaceutics Journal Impact IF Highest IF 6.072 Key Factor Analysis Lowest IF 0.857 Key Factor Analysis Total Growth Rate 608.5% Key Factor Analysis Annual Growth Rate 60.9% Key Factor Analysis Pharmaceutics Journal Key Metrics Pharmaceutics

Recent highlights from the journal. antimicrobials illustration. Virtual Issues. Antimicrobials. This Virtual Issue features articles from various ACS journals ...

09.01.2022 · The Molecular Pharmaceutics Latest Impact Factor IF 2021-2022 is 4.939. More Molecular Pharmaceutics Impact Factor Trend, Prediction, Ranking & …

JCR Pharmaceuticals Co., Ltd. Headquarters: 3-19 Kasuga-cho Ashiya, Hyogo, 659-0021 Japan: Representative: Shin Ashida Chairman and President: Founded: September 1975: Paid-in Capital: JPY 9,061million: Employees: 719 (As of March 31, 2021) Listed on: Tokyo Stock Exchange First Section (Securities code:4552) Scope of Business

Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and ...

Pharmaceutics Latest Impact Factor IF 2021-2022 is 6.072. ... yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR).

Pharmaceutics is a journal covering the technologies/fields/categories related to Pharmaceutical Science (Q1). It is published by MDPI ...

International Journal of Pharmaceutics: X Metrics 2.7 weeks Time to First Decision The average number of weeks it takes for an article to go from manuscript submission to the initial decision on the article, including standard and desk rejects 5.1 weeks Review Time

Pharmaceutics | An Open Access Journal from MDPI Pharmaceutics Pharmaceutics is a peer-reviewed, open access journal on the science and technology of pharmaceutics and biopharmaceutics, and is published monthly online by MDPI.

Mar 23, 2021 · JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases...

This site uses cookies to improve your experience on the site. Please see our Cookie Policy for more information. By continuing to browse this site, you agree to the use of cookies.

1 day ago · JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America.